Allink Biotherapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $50M

  • Investors
  • 11

Allink Biotherapeutics General Information

Description

Developer of oncology drugs intended to discover and advance antibody-based therapeutics for oncology and immunology. The company offers integrated platforms for bispecific antibody engineering, conjugation chemistry for antibody-drug constructs, preclinical data assembly, and clinical-stage program management informed by biomarker strategies, enabling biopharma teams, clinical researchers, and translational scientists to evaluate targets rigorously, structure trials more efficiently, and progress candidates with traceable methods and documented performance across multiple disease areas.

Contact Information

Website
www.allinkbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10th Floor, Building 2, Jinchuang Building
  • Number 4560 Jinke Road, Pudong New Area
  • Shanghai, 201422
  • China
+86 189
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 10th Floor, Building 2, Jinchuang Building
  • Number 4560 Jinke Road, Pudong New Area
  • Shanghai, 201422
  • China
+86 189

Allink Biotherapeutics Timeline

202420252026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allink Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A1) 16-Dec-2025 $50M Completed Generating Revenue
4. Secondary Transaction - Private 14-Mar-2025 Completed Generating Revenue
3. Secondary Transaction - Private 17-Jan-2025 Completed Generating Revenue
2. Early Stage VC (Series A) 27-Nov-2024 $42M $42M Completed Generating Revenue
1. Seed Round 03-Nov-2023 Completed Startup
To view Allink Biotherapeutics’s complete valuation and funding history, request access »

Allink Biotherapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
5Y Capital Venture Capital Minority
Lapam Capital Venture Capital Minority
Meituan Corporation Minority
Suzhou Equity Investment Fund Management Fund of Funds Minority
Gaorong Ventures Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Allink Biotherapeutics FAQs

  • When was Allink Biotherapeutics founded?

    Allink Biotherapeutics was founded in 2023.

  • Where is Allink Biotherapeutics headquartered?

    Allink Biotherapeutics is headquartered in Shanghai, China.

  • What industry is Allink Biotherapeutics in?

    Allink Biotherapeutics’s primary industry is Drug Discovery.

  • Is Allink Biotherapeutics a private or public company?

    Allink Biotherapeutics is a Private company.

  • What is Allink Biotherapeutics’s current revenue?

    The current revenue for Allink Biotherapeutics is .

  • How much funding has Allink Biotherapeutics raised over time?

    Allink Biotherapeutics has raised $89M.

  • Who are Allink Biotherapeutics’s investors?

    5Y Capital, Lapam Capital, Meituan, Suzhou Equity Investment Fund Management, and Gaorong Ventures are 5 of 11 investors who have invested in Allink Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process